Observational Study of the Effectiveness of Synagis Immunoprophylaxis in Preterm Infants With High Risk of Severe Respiratory Syncytial Virus Infection.
Phase of Trial: Phase IV
Latest Information Update: 30 Oct 2012
At a glance
- Drugs Palivizumab (Primary)
- Indications Respiratory syncytial virus infections
- Focus Therapeutic Use
- Acronyms INSPIRA
- Sponsors Abbott Laboratories
- 10 Mar 2011 Actual end date (Feb 2011) added as reported by ClinicalTrials.gov.
- 10 Mar 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 08 Jul 2010 Planned end date changed from 1 Nov 2010 to 1 Mar 2011 as reported by ClinicalTrials.gov.